Biomedical Research Unit: Acute and Chronic effects of transcranial Direct Current stimulation in Lewy body dementia patients (BRU ACDC-Study)

ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 40 人开始时间: 2013年10月25日最近更新: 2019年2月11日

适应症

试验速览

•1. Age > 60, either sex
•2. Provision of written informed consent or, if lacking capacity, consent provided by legal or other appropriate representative in accordance with provisions of the 2005 Mental Capacity Act
•3. Absence of concurrent major psychiatric illness (e.g. major depression)
•4. Absence of severe physical illness or comorbidity that may limit ability to fully participate in study
•5. Sufficient English to allow assessment scales and cognitive testing
•For Lewy body dementia participants:
•1. MMSE>12
•2. Meet criteria for probable DLB or probably PDD
•3. If taking anticholinesterase drugs, memantine, antipsychotic medication and/or antiparkinsonian medication ? need to be stable on these agents for at least 1 month
•4. Presence of reliable informant sufficient to provide information for informant rated scales
•5. Evidence of persistent and recurrent visual hallucinations of a moderate to severe nature occurring in the month prior to inclusion in the study

•1. Skin allergies or sensitivities to electrode gels or any significant dermatological / scalp disease
•2. Past history excess alcohol intake
•3. History of moderate to severe visual impairment secondary to glaucoma, cataract, or macular degeneration
•4. Metallic implants in the head/neck area or electronic implants of any kind (including pacemakers)
•5. Past history of other neurological illness including, but not limited to stroke, intracerebral pathology and epilepsy
•6. Psychotropic and other medications which may significantly interfere with cognitive testing and tDCS efficacy (including high dose antipsychotics, dopamine agoinsts, sedative antidepressants, benzodiazepines except when low dose and used as hypnotics or treatment for REM-sleep behaviour disorder and centrally acting anticholinergic drugs)

发起方

ewcastle upon Tyne Hospitals NHS Foundation Trust (UK)